Weight Regain After Stopping Wegovy or Zepbound: What the Latest Studies Show

Written byDr. Trace Curry, MD, FASMBSFounder & Medical Director

✓

Medically reviewed byDr. Trace Curry, MD, FASMBSMedical weight management

✓

Updated & clinically reviewedSeptember 10, 2026Latest evidence update

✓

Clinical review teamJourneyLite Clinical Editorial TeamMedical editorial policy →

Weight regain after stopping Wegovy or Zepbound is common, and it can begin within months. The latest research helps explain how quickly it happens, why published estimates differ, and how continued obesity care can change the outcome.

Wegovy contains semaglutide; Zepbound contains tirzepatide, which acts on both GIP and GLP-1 receptors. Both can produce meaningful weight loss. The challenge for many patients is maintaining progress when coverage ends, side effects interfere, or treatment stops.

How Fast Does Weight Return After Stopping GLP-1 Medication?

There is no single regain rate that applies to everyone. Studies differ in the medication used, initial weight loss, time on treatment, and care after discontinuation.

The August 2026 analysis: about 2.3 pounds per month

A reanalysis published August 31, 2026 combined six semaglutide or tirzepatide studies with 1,776 participants. It estimated an average regain rate of 1.04 kg, or about 2.3 pounds, per month. The model projected that half the initial weight loss would return by 7.5 months.

This was a new analysis of existing studies, not a new group of patients. Observed follow-up after stopping treatment ranged from 4 to 52 weeks. Its projection of returning to starting weight at 15 months assumes regain continues at a constant rate beyond the observed period. It should not be treated as a deadline or prediction for an individual patient. Read the August 2026 analysis.

The January 2026 BMJ review: a broader view

The BMJ review included 37 studies and 9,341 participants across weight-management medications. Average regain was approximately 0.4 kg per month across all medications, and 0.8 kg per month—about 1.8 pounds—after newer drugs such as semaglutide and tirzepatide. Its estimated return to baseline at roughly 1.5 years for the newer drugs was also a projection. The August analysis reused the semaglutide and tirzepatide studies from this review, so these are overlapping sources of evidence. Read the BMJ systematic review.

What was actually observed after stopping semaglutide?

In the STEP 1 extension, participants previously treated with semaglutide lost an average of 17.3% of their starting weight. During the year after medication and structured lifestyle support stopped, they regained 11.6 percentage points, approximately two-thirds of the weight they had lost. Their average net loss was still 5.6% below baseline. This describes that study group; it does not mean two-thirds of all patients regain all their weight. Read the STEP 1 extension.

Does everyone eventually regain all the weight?

No study can promise an individual outcome. A separate 2026 analysis in EClinicalMedicine used a model in which regain slows over time. Drawing on six randomized trials with 3,236 participants, it estimated that 60% of the weight lost was regained at one year. Beyond one year, it projected a plateau at about 75% regained, leaving some benefit. That longer-term plateau was modeled, not directly observed. Read the nonlinear weight-regain analysis.

Why a 2026 Cleveland Clinic Study Found Much Less Average Regain

A study published online in March 2026 followed 7,938 patients who stopped semaglutide or tirzepatide within 3–12 months of starting. Among those treated for obesity, average loss before stopping was 8.4%. Over the next year, average regain was only 0.5% of body weight measured at discontinuation.

However, many patients received further care: 19.6% restarted the original medication and 35.2% received an alternative obesity treatment. These categories can overlap. Outcomes varied considerably between individuals. Read the Cleveland Clinic discontinuation study.

This observational study describes what happened after patients stopped a particular drug, not necessarily after they stopped all obesity treatment. It supports discussing a maintenance plan rather than assuming every patient will follow the same regain curve.

How Do GLP-1 Long-Term Results Compare With Surgery?

A study published online June 25, 2026, in Obesity compared 44,025 adults with BMI of at least 35 across two health systems. Estimated average weight loss at two years was:

All four figures use starting body weight as the denominator. They are total weight loss, not excess weight loss.

This retrospective comparison included medication starters, not only people who continuously took an optimal dose. In a separate analysis requiring a year of continuous medication orders, two-year loss was 8.0% with semaglutide and 11.9% with tirzepatide. Surgery was associated with greater loss, but the groups were not randomized and individual results vary. Read the medication-versus-surgery study.

Does Less Weight Loss in Real-World Studies Mean GLP-1s Do Not Work?

No. Treatment interruptions, dose, tolerability, and access all matter. A 2025 Cleveland Clinic study reported average one-year weight loss of approximately 3.6% in early discontinuers, 6.8% in later discontinuers, and 11.9% in people who continued treatment. Outcomes were better at higher maintenance doses. Read the 2025 Cleveland Clinic findings.

Weight regain after stopping a medication and inadequate weight loss while taking it are different problems. Your care team should review your treatment duration, dose, response, side effects, and health goals before deciding whether to continue, adjust, or change treatment.

Do You Have to Take Wegovy or Zepbound Forever?

Many patients benefit from long-term medication because obesity is a chronic disease. When treatment stops, the appetite-control effect can fade while the biological drive to regain weight remains.

That does not mean every patient must stay on the same drug at the same dose for life. The evidence supports ongoing obesity care. Continued medication, a clinician-directed maintenance dose, a different medication, surgery, or combined care may be appropriate. The plan should reflect your health, treatment response, tolerability, and access.

What to Discuss Before Stopping or Switching Medication

• Explain why treatment may stop. Coverage, affordability, side effects, and disappointing results call for different solutions.
• Arrange follow-up before the final dose. Ask how your team will monitor weight, appetite, and relevant health conditions after a change.
• Build a nutrition and activity plan. Dietitian support, adequate nutrition, and physical activity suited to your health remain part of maintenance care.
• Review treatment alternatives. Another medication or a surgical consultation may be appropriate if the current plan is not sustainable.
• Contact your prescriber before restarting after a gap. Ask about the appropriate restart plan rather than resuming a previous high dose on your own.

If treatment has already stopped and weight is returning, seek help early. JourneyLite offers medical weight management and surgical evaluation so the next step can match your needs.

Why GLP-1 Weight Regain Happens

Patients sometimes feel embarrassed when they regain weight after stopping Wegovy or Zepbound. They should not.

Weight regain after stopping GLP-1 medications is not a character flaw. It is biology.

When GLP-1 Medications May Be a Good Fit

GLP-1 medications can be a very reasonable option for many patients.

They may be a good fit for a patient who:

• Has obesity or overweight with weight-related medical problems.
• Wants a non-surgical treatment.
• Has insurance coverage or can afford long-term treatment.
• Tolerates the medication well.
• Is comfortable with ongoing medication use.
• Has a plan for nutrition, activity, protein intake, and follow-up.
• Needs help with appetite control before or after bariatric surgery.

At JourneyLite, we offer medical weight loss and GLP-1 treatment pathways for appropriate patients. I do not view medication as “less serious” than surgery. Obesity medicine is real medicine, and medication can be an important tool.

The question is whether it is the right long-term tool for a specific patient.

When Gastric Sleeve or Gastric Bypass May Be a Better Long-Term Option

For patients with more severe obesity, repeated weight regain, type 2 diabetes, sleep apnea, high blood pressure, joint pain, or a long history of unsuccessful dieting, bariatric surgery may offer a more durable treatment.

Gastric sleeve and gastric bypass work differently than GLP-1 medications. They do not simply reduce willpower demands. They change hunger, fullness, gut hormone signaling, portion tolerance, and metabolic function.

At JourneyLite Surgery Center in Cincinnati, we specialize in outpatient bariatric surgery, including gastric sleeve, gastric bypass, revisional bariatric surgery, and lap band management. We have been helping patients with weight loss since 2008 and serve patients from Cincinnati, Dayton, Columbus, Northern Kentucky, Indiana, Indianapolis, and beyond.

A 2025 Cleveland Clinic study published in Nature Medicine compared metabolic surgery with GLP-1 receptor agonist treatment in patients with obesity and type 2 diabetes. The study found that surgery was associated with greater long-term weight loss and lower risks of several major health outcomes, including all-cause mortality, compared with GLP-1 medication alone.
Read the Nature Medicine study.

At JourneyLite, we are direct about these realities. Bariatric surgery is powerful, but it is not magic. It is a tool that works best with experienced surgical care, dietitian support, realistic expectations, and long-term follow-up.

Surgery and GLP-1 Medications Are Not Always Competitors

One of the biggest mistakes in obesity treatment is framing the decision as “medication versus surgery” for every patient.

Sometimes the best answer is medication. Sometimes the best answer is surgery. Sometimes the best answer is both.

For example, a patient may use a GLP-1 medication before surgery to lower operative risk. Another patient may have gastric sleeve surgery and later use a GLP-1 medication for weight regain or increased appetite years later. A patient with very high BMI may need a staged plan. A patient who is not ready for surgery may start with medical weight loss or a gastric balloon.

The best obesity treatment plan is individualized.

Practical Examples: Which Patient May Fit Which Treatment?

Choosing a Sustainable Long-Term Treatment Plan

GLP-1 medications are valuable obesity treatment tools. Wegovy, Zepbound, semaglutide, and tirzepatide can produce meaningful weight loss for many patients.

But recent data show several important limitations:

• Real-world results are often less dramatic than clinical trial results.
• Many patients discontinue treatment within the first year.
• Lower doses may produce less weight loss.
• Weight regain is common after stopping medication.
• Long-term success often requires long-term treatment.
• Patients with severe obesity may need a more durable option.

As a bariatric surgeon and obesity medicine physician, my advice is simple: do not choose a treatment based only on what is popular right now. Choose the treatment that matches your medical history, BMI, weight-loss goals, risk tolerance, insurance situation, and ability to follow through long term.